Revance Therapeutics (RVNC) Misses Q2 EPS by 12c

Revance Therapeutics (NASDAQ: RVNC) reported Q2 EPS of ($0.88), $0.12 worse than the analyst estimate of ($0.76). Revenue for the quarter came in at $28.4 million versus the consensus estimate of $28.15 million.

For earnings history and earnings-related data on Revance Therapeutics (RVNC) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Ridgepost Capital acquires Stellus Capital Management for $4B AUM
• Accenture downgraded by TD Cowen on AI concerns